Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer
β Scribed by Hirotaka Iwase; Shunzo Kobayashi; Yukashi Itoh; Hideki Fukuoka; Tatsuya Kuzushima; Hiroji Iwata; Toshinari Yamashita; Akihiro Naitoh; Kazuko Itoh; Akira Masaoka
- Publisher
- Springer US
- Year
- 1995
- Tongue
- English
- Weight
- 431 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0167-6806
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Ninety-eight premenopausal patients with stage IV breast cancer were treated with chemoimmunotherapy alone, or with combination oophorectomy-chemoimmunotherapy either simultaneously (chemoimmunotherapy within four weeks of oophorectomy) or sequentially (delayed chemoimmunotherapy until evidence of p
A novel tumor marker, tumor-associated glycoprotein-72 (TAG-72), has been identified using monoclonal antibody (MAb) B72.3. Using immunohistochemical techniques, TAG-72 has been found in carcinomas of various origin including colon, stomach, breast, lung, prostate, and ovary, as well as in body flui
BACKGROUND. β£-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH) closely follow the course of germ cell tumors (GCTs) and are widely used for diagnosis, prognosis, and follow-up purposes. The objective of this study was to assess the concordance of tumor markers a